Algert Global LLC Grows Stock Holdings in LivaNova PLC (NASDAQ:LIVN)

Algert Global LLC increased its position in shares of LivaNova PLC (NASDAQ:LIVN) by 81.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 105,017 shares of the company’s stock after purchasing an additional 47,008 shares during the period. Algert Global LLC owned 0.19% of LivaNova worth $5,518,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Point72 Asset Management L.P. raised its holdings in LivaNova by 204.3% during the second quarter. Point72 Asset Management L.P. now owns 1,285,636 shares of the company’s stock worth $70,479,000 after purchasing an additional 863,157 shares in the last quarter. First Light Asset Management LLC raised its stake in LivaNova by 591.1% during the 2nd quarter. First Light Asset Management LLC now owns 710,390 shares of the company’s stock worth $38,944,000 after acquiring an additional 607,598 shares in the last quarter. Great Lakes Advisors LLC acquired a new position in LivaNova in the second quarter valued at $16,614,000. Driehaus Capital Management LLC boosted its stake in LivaNova by 64.7% in the second quarter. Driehaus Capital Management LLC now owns 544,042 shares of the company’s stock valued at $29,824,000 after acquiring an additional 213,749 shares in the last quarter. Finally, Perceptive Advisors LLC grew its holdings in shares of LivaNova by 48.5% during the second quarter. Perceptive Advisors LLC now owns 444,000 shares of the company’s stock worth $24,340,000 after purchasing an additional 145,000 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

LIVN has been the subject of several research reports. The Goldman Sachs Group assumed coverage on LivaNova in a report on Friday, October 4th. They issued a “buy” rating and a $65.00 target price for the company. Robert W. Baird increased their price objective on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. Needham & Company LLC reaffirmed a “buy” rating and issued a $75.00 target price on shares of LivaNova in a report on Tuesday, November 12th. Baird R W upgraded shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 17th. Finally, Mizuho lowered their price objective on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, October 31st. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $69.17.

LivaNova Stock Down 0.7 %

Shares of LivaNova stock opened at $51.32 on Monday. The company has a market cap of $2.79 billion, a P/E ratio of 122.19 and a beta of 1.01. The firm has a fifty day moving average of $52.13 and a two-hundred day moving average of $52.45. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. LivaNova PLC has a one year low of $42.75 and a one year high of $64.47.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.